Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Update

Sutro Biopharma, Inc. (NASDAQ:STRO) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 528,233 shares, a growth of 30.5% from the December 31st total of 404,777 shares. Currently, 6.6% of the company’s shares are sold short. Based on an average daily volume of 130,917 shares, the days-to-cover ratio is currently 4.0 days. Based on an average daily volume of 130,917 shares, the days-to-cover ratio is currently 4.0 days. Currently, 6.6% of the company’s shares are sold short.

Hedge Funds Weigh In On Sutro Biopharma

Several hedge funds have recently modified their holdings of STRO. Catalyst Funds Management Pty Ltd acquired a new position in shares of Sutro Biopharma in the 2nd quarter valued at about $27,000. Bridgeway Capital Management LLC lifted its holdings in Sutro Biopharma by 232.6% in the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after acquiring an additional 30,000 shares during the period. Savant Capital LLC purchased a new stake in Sutro Biopharma in the 2nd quarter worth approximately $37,000. CWM LLC boosted its position in Sutro Biopharma by 73.2% in the 2nd quarter. CWM LLC now owns 56,657 shares of the company’s stock worth $40,000 after purchasing an additional 23,941 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Sutro Biopharma by 174.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company’s stock worth $43,000 after purchasing an additional 38,561 shares during the period. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Stock Performance

NASDAQ:STRO traded down $0.33 during midday trading on Tuesday, reaching $14.78. 62,674 shares of the stock traded hands, compared to its average volume of 121,648. The stock has a market capitalization of $125.74 million, a PE ratio of -0.57 and a beta of 1.54. Sutro Biopharma has a 12-month low of $5.23 and a 12-month high of $21.25. The business has a 50-day moving average of $11.39 and a two-hundred day moving average of $9.85.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.25). Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 206.77%.The business had revenue of $9.69 million during the quarter, compared to analyst estimates of $10.14 million. Research analysts anticipate that Sutro Biopharma will post -2.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

STRO has been the topic of a number of recent research reports. HC Wainwright increased their price target on Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a research report on Monday, December 22nd. Wall Street Zen lowered shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Citigroup raised shares of Sutro Biopharma to an “outperform” rating in a research report on Tuesday, January 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a report on Monday, December 22nd. Finally, Wedbush reiterated a “neutral” rating and set a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $31.83.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.